However, EBITDA (earnings before interest, tax, depreciation and amortization) margin declined by 107 bps to 23.6 per cent YoY.
"The company has a strong product portfolio with strong pricing power. The management, however, is currently concentrating more on driving volume with deeper penetration with distribution expansion. Current sales numbers where domestic business grew by 13 per cent signifies the same considering weaker demand scenario," analysts at Narnolia Financial Advisors said in result update.
Going forward, the company’s continued focus on innovating and renovating its brands, new launches in nutrition segment, emphasis on expanding penetration in categories where penetration is relatively low, is expected to drive revenue growth. Change in product mix and judicious pricing is likely to cushion declining margin in the wake of higher input prices, the brokerage firm said, with ‘buy’ rating on the stock and target price of Rs 13,472 per share.